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Summary 
While all known microbial superantigens are mitogenic for human peripheral blood lymphocytes 
(PBL),  the functional response induced by Mycoplasma arthritidis-derived superantigen (MAM) 
is unique in that/CLAM stimulation of PBL consistently results in T ceLl-dependent  B cell activation 
characterized by polyclonal IgM and IgG production. These immunostimulatory  effects of MAM 
on the humoral arm of the human immune system warranted a more precise characterization 
of MAM-reactive human T  cells. Using an undoned MAM reactive  human T  cell line as 
immunogen, we have generated a monoclonal antibody (mAb) (termed C1) specific for the T 
cell receptor VB gene expressed by the major fraction of MAM-reactive human T cells, VB17. 
In addition, a VB17-  MAM-reactive T  cell population exists,  assessed by MAM, induced T 
cell proliferation and cytotoxic T cell activity, mAb C1 will be useful in characterizing the functional 
properties of V~17 + T  cells and their potential role in autoimmune disease. 
T 
he term superantigen (SA)  1 has been applied to a class 
of T  cell mitogens, including a group of endogenous 
murine retroviral gene products (1-4)  and several microbial 
toxins (5-7),  which share  a  unique set  of characteristics. 
Specifically, SA bind with high affinity to regions of MHC 
class II molecules distinct from the conventional peptide 
binding groove (8-14), and are mitogenic for T cells in the 
absence of processing (15). T cell responsiveness to SA is dic- 
tated exclusively by TCR VB gene family usage, with little 
influence by other TCR variable elements (5, 16-18). In ad- 
dition, SA are among the most powerful mitogens known, 
functioning at nanomolar to fentamolar concentrations (7, 
1 Abbreviations used in this paper: EAE,  experimental  allergic encephalo- 
myelitis; MAM, M2/coplasraa  arthritidis-derived  superantigen; MBP, myelin 
basic  protein;  MS,  multiple  sclerosis; RA,  rheumatoid  arthritis;  SA, 
superantigen; SE, staphylococcal enterotoxin; TSST, toxic shock syndrome 
toxin. 
19, 20). Together, these characteristics render the SA capable 
of profound effects on immune system function. 
To date the clinical impact of microbial SA has been most 
clearly associated with acute systemic illnesses, often mani- 
fest by shock and immunosuppression which are thought to 
result from the massive release of cytokines following SA ac- 
tivation of a substantial fraction of the T cell pool (21). Ex- 
amples include toxic shock syndrome, caused by the Staphy- 
lococcus aureus-derived  toxin  (TSST-1) (22-24),  and  food 
poisoning or shock induced by the Staphylococcal  enterotoxins 
(SEs) (21, 25). The potential for SA to initiate more subtle 
perturbations of the immune system, leading to B cell acti- 
vation, hypergammaglobulinemia and, perhaps, autoimmu- 
nity has  been  suggested (5,  26-28).  In  this context,  the 
Mycoplasma arthritidis-derived SA, termed MAM, is of par- 
ticular interest. The in vitro response of human PBL to MAM 
is distinct from that induced by the Staphylococcus  aureus-derived 
SA in at least two respects: (a) the level ofT cell proliferation 
induced by MAM is much more modest (29) and (b) the re- 
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donal immunoglobulin production (Crow, M.K., Z. Chu, 
B.  Ravina,  G. Zagon, J.R.  Tumang, B.C.  Cole,  and S.M. 
Friedman, manuscript submitted for publication). These in 
vitro observations in man, coupled with the unique capacity 
ofM. arthritidis to induce a chronic, inflammatory polyarthritis 
in genetically-susceptible strains of rodents (30), suggest that 
the identification and characterization of MAM-reactive human 
T  cells may prove useful for evaluating the potential role of 
MAM-like SA in autoimmune responses. Here, we describe 
the generation of a mAb to the TCIL V/3 gene product used 
by the major fraction of MAM reactive human T calls, which 
was determined to be V/~17. 
Materials  and Methods 
Reagents.  Staphylococcal enterotoxins SEA, SEB, SEC1, SEC2, 
SEC3, and SEE, as well as toxic shock syndrome toxin (TSST-1), 
were obtained from Toxin Technology (Madison,  WI). Partially 
purified MAM was isolated from M. arthritidis culture superuatants 
as previously described (7). All SA were used at a final concentra- 
tion predetermined to be optimal for T cell proliferation,  1:4,000 
for MAM and 10-25 ngm/ml for the Staphylococcal-derived SA. 
Isolation and Fractionation of  Lymphocytes.  Fresh peripheral blood 
or tonsil lymphocytes were isolated by Ficoll-Hypaque centrifuga- 
tion. T cells were isolated from non-T ceils by E-rosette formation 
with neuraminidase-treated sheep red blood cells and a second Ficoll- 
Hypaque centrifugation. Residual T cells were removed from the 
non-T cell fraction by treatment with anti-CD3 followed by the 
addition of magnetic beads coated with goat anti-mouse antibody 
(Dynal, Inc., Great Neck, NY) and physical separation of the bead- 
bound T  cells utilizing a magnet. 
Generation of SA-reactive T Helper (Th) Cell Lines.  CD4 + pe- 
ripheral blood T ceUs were isolated from unselected T cell popula- 
tions by incubating T cells with an excess of anti-CD8 mAb fol- 
lowed by washing and physical removal of T cells binding antibody 
to CD8 using magnetic beads coated with goat anti-mouse anti- 
body (Dynal, Inc.)  and a magnet. The CD4+-enriched popula- 
tions  were  cocultured with  x-irradiated  autologous  APC  and 
either  MAM  or  SEE. After  5  d,  semi-purified  human  IL-2 
(Electro-Nucleonics,  Inc., Fairfield, NJ) was added. Cultures were 
retriggered weekly with APC~, and the relevant SA, and expanded 
in the presence of IL-2. Cell lines were maintained in culture media 
consisting of RPMI 1640 (Gibco Laboratories, Grand Island, NY) 
containing 10% fetal bovine serum (Whittaker, M.A. Bioproducts, 
Walkersville, MD), penicillin and streptomycin (50 U/ml, Gibco 
Laboratories),  and 2 mM glutamine (Gibco Laboratories). 
CD23 Induction Assay.  The induction of B ceU surface CD23 
expression by Th cells has been detailed previously  (31). Briefly, 
5  x  10  s purified tonsillar B ceils were cultured in final medium 
with 1.5  x  10  s x-irradiated  CD4 + MAM- or SEE-reactive TCL 
cells. Cultures were supplemented with final medium alone  or 
medium containing an optimal concentration of the various SA. 
After 16 h, B cells were assayed for CD23 expression by indirect 
immunofluorescence staining using mAb EBVCS2 (generously do- 
nated by Dr. Bill Sugden and Stan Metzenberg, Madison, WI) and 
counterstained with fluorescein-conjugated  F(ab')2 fragments of 
goat anti-mouse IgG (Tago, Inc., Burlingame, CA). The percentage 
of positively staining calls was determined by analysis on an Ortho 
IIs cytofluorograph (Ortho Diagnostic Systems, Inc., Westwood, 
MA). 
Generation of TCL Enriched for Specific TCR  V  Gene Usage. 
Tonsil T cell aliquots were incubated at room temperature with 
saturating concentrations of TCK V  gene specific mAb:  C37 
(V/~ 5.2/5.3) (32) (unpublished data, DN Posnett), OT145 (VB6.7a) 
(33, 34), $511 (VB12) (17), Ti3a (VBS) (35), and C1. After 30 rain, 
cells were washed three times, resuspended  in final medium and 
cultut~t at a final concentration of 0.5  x  l&/ml in the presence 
of goat anti-mouse antibody-coated magnetic beads (Dynal, Inc.). 
Beads were added at a ratio of 20 beads to 1 target T cell. After 
5 d, magnetic beads were removed, the T cells washed and recul- 
tured with I1.-2 alone for 48 h. Cultures were maintained with 
Ib2 and weekly feeding with periodate-treated  allogeneic non-T 
feeder cells. These cultures become highly enriched in T cells ex- 
pressing the relevant VB gene, depending on the initial mAb used 
for stimulation. Usually, this occurs over a 6-d period.  Occasion- 
ally, a second cycle of stimulation was required to achieve greater 
than 95%  specific V/S expression.  At the time these TCL were 
utilized as effectors in the cytolytic assay or for KNA isolation, 
each was virtually 100% + for T cells expressing the appropriate 
TCK V gene products. 
Assay ofSA-delx*ndent Cytdysis.  TCL cells were assayed  for cyto- 
lyric activity in a 4-h SlCr release assay (36), using MHC class II 
antigen-bearing target ceUs, B cell lymphoblastoid cell line 8866. 
Briefly, 8866 cells were incubated for 2 h at 37~  with SlCr in 
the presence of final medium alone, or the indicated SA. Target 
ceils were washed and mixed in triplicate  with varying numbers 
of TCL effector ceils. Data is presented  as mean percent lysis of 
target ceils at each effector to target cell ratio. 
Iramunoprecipitation of TCR  Utilizing mAb  C.I.  A  MAM- 
reactive TCL with 60% C1 + T cells was radioiodinated with lac- 
toperoxidase and peroxide, using 25  x  106 cells and 2.5 mCi 12sI. 
Cell lysis and immunoprecipitations  with SPA-Sepharose and mono- 
clonal antibodies  were performed as described  (37). 
Analysis of TCR Vf3 Gene Usage by Polymerase Chain Reaction 
(PCR).  Three T cell lines were prepared by stimulating normal 
peripheral blood T cells with either OT145 (Vf16.7), C37 (V~5.2/ 
5.3) or C1 MAb (see above). Total cellular RNA was isolated from 
each cell line by the acid guanidinium thiocyanate-phenolchloroform 
method (38). cDNA was synthesized with reverse transcriptase, 
using an anti-sense C/~ primer (see below) (34). The PCR was per- 
formed with a pand of VB specific sense primers, in paralld reac- 
tions where each VB primer was matched with the CB anti-sense 
primer situated 55 bp from the 5' end of the C region. Two paired 
Cc~ primers were used as a positive control. Each cDNA prepara- 
tion was tested for the optimal dilution. PCK conditions included 
primers at 0.5/~M. Replinase (Dupont) 2 U, buffer containing 3.0 
mM MgCI (20 x  buffer, Dupont), 32dCTP 20/~Ci, cold dNTPs 
at 0.2 mM, in a final volume of 0.02 ml. Amplification was done 
for I min at 94~  1 rain at 51~  and 1 rain at 72~  for 25 cycles. 
PCR products were analyzed on a 5% polyacrylamide gel. The 
gel was dried and exposed to film. 
PCtL primers used in the experiment shown in Fig. 7 were: CB 
(anti-sense)  5' CTTCTGATGGCTCAAACAC 3'; Cc~ 5' (sense) 
5' GAACCCTGACCCTGCCGT 3'; Ct~ 3' (anti-sense) 5' TCA- 
TAAATTCGGGTAGGATC  3'; V/~2 (sense) 5' GTTTCTCATC- 
AACCATC~AA 3'; VB6 (sense) 5' TCAGGTGTGATCCAATT'IE 
3'; VB5.3/5.2 (sense) 5' GTCAGGGGCCCCAGTTTAT 3'; V/~17 
(sense) 5' ACAGCGTCTCTCGGGAGA 3'. 
Immunofluorescence.  Single color immunofluorescence was per- 
formed as previously described (31). Two-color immunofluorescence 
was prepared by first incubating 5  x  10  s cells with various mAb 
for 30' at room temperature. This was followed by three washes 
in  PBS-BSA 1%,  azide  0.02%,  and goat anti-mouse Ig-FITC 
(GAM-FITC) for 30' at room temperature.  The cells were washed 
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flee GAM-FITC binding  sites for 30' at room temperature.  The 
cells were washed 3 x  and incubated with PE-labeled anti-CD4 
or anti-CD8 mAb (UBI/Olympus, Lake Success, NY) for 30' at 
room temperature. The cells were finally washed 3 x  and analyzed 
on an ORTHO cytofluorograph. The results shown in Table 1 rep- 
resent  the ratio of double positive (FITC  +  PE) cells over total 
CD4 or CD8 positive cells expressed as a percentage. 
Results 
Rationale and Strategy for the Development of mAb Specific 
fddor  MAM-reactive Human TCRs.  The Mycoplasma arthritidis- 
erived SA, termed MAM, became of special interest during 
studies which compared the effects of a panel of microbial 
SA on human PBL function (Crow, M. K., Z. Chu, B. Ra- 
vina,  G.  Zagon,  J.  K.  Tumang,  B.  C.  Cole,  and  S.  M. 
Friedman, manuscript submitted for publication). These ex- 
periments demonstrated that MAM is unique among the SA 
tested, induding TSST-1 and the SEs, in its capacity to reprodu- 
cibly trigger polyclonal T  cell-dependent Ig production by 
unselected human PBL. It should be emphasized that the Staph- 
ylococcus aureus-derived  SA can support  a polyclonal Ig re- 
sponse, but, in most instances, require culture conditions in 
which T cell proliferation is inhibited, e.g., cultures containing 
purified responder B cells and small numbers of x-irradiated 
autologous T  cells  (26). 
To understand how MAM activation of PBL so effectively 
drives the humoral arm of the immune system, and to char- 
acterize MAM-reactive human T  cells,  a mAb against  the 
MAM binding TCR was generated. Since no MAM-reactive 
T call clones were available, it was reasoned that a polyclonal 
MAM-reactive TCL could serve as a successful immunogen 
if MAM-responsive T cells represent a fraction of the T cell 
repertoire,  which is highly restricted with respect to TCK 
VB gene usage. To this end, we took advantage of the fact 
that the specific interaction of SA-reactive  CD4 + human T 
cells  and SA-bearing B cells  results in the rapid expression 
of the CD23 activation antigen on a fraction of the resting 
B cell pool (28),  Using this assay, we compared the CD23 
induction profiles of CD4 + MAM-reactive and a number of 
Staphylococcus aureus SA-reactive TCL. CD4 + MAM-reactive 
TCL induce maximal CD23 expression on B cells which have 
bound MAM,  SEA, SEB,  SEC1,  SEC2,  or SEC3,  while a 
minimal CD23 response is induced on B cells bearing either 
tEE or TSST-1  (data not shown).  Conversely, CD4 § SEE- 
reactive TCL cells induce optimal CD23 expression on B cells 
bearing TSST-1  or any of the SEs, but trigger little CD23 
expression by MAM bearing B cells (data not shown). This 
functional evidence of crossreactivity by SA-activated TCL 
cells is consistent with reports that activated human T  cells 
are somewhat promiscuous in their proliferative responses to 
the staphylococcal-derived SA (39).  Importantly,  however, 
the pattern of CD23 expression observed suggest that MAM 
and tEE-specific human  T  cells  show little cross-reactivity 
and may therefore utilize different TCR V3 gene products. 
Thus, the tEE-reactive TCL should provide an excellent com- 
parison  for screening  MAM-specific TCR mAbs. 
Given these considerations, Balb/c mice were immunized 
on four occasions with MAM-reactive TCL cells which had 
been expanded in long-term  culture (7 wk) by weekly re- 
stimulation  with  autologous APC and MAM.  Three days 
after the final  immunization,  the mice were sacrificed  and 
their splenocytes fused with SP2/0 myeloma cells.  Hybrid- 
omas which demonstrated  reactivity with a small fraction 
of freshly isolated (resting) peripheral T cells were screened 
against the MAM-reactive TCL used for immunization  and 
an SEE-reactive TCI~derived from the same donor.  In this 
manner, a mAb termed C1, was identified. As shown in Fig. 
1, C1 stains between 3-6% of peripheral T  cells,  >60%  of 
the MAM-reactive TCL used as immunogen,  and virtually 
no SEE-reactive TCL cells. Immunoprecipitation studies (Fig. 
2) showed that mAb C1 recognizes a disulfide-linked hetero- 
dimer consistent with the ol/3 TCK. Finally, as with other 
TCR mAb specific for V gene products, C1 recognizes a small 
subset of peripheral T cells from all donors tested, including 
samples of cord blood T  cells.  While C1 + cells are found 
among both CD4 + and CD8 + T  cells,  some donors show 
selective enrichment  of C1 § T  cells in one or the other T 
cell subset (Table  1). 
mAb C1 was used to screen a number of SA-reactive TCL 
propagated in vitro.  As shown (Table 2) short term activa- 
tion of peripheral  T  cells with a panel of SA demonstrates 
a clear enrichment of C1 § cells among the T  cells activated 
by MAM and several of the SE with which MAM-specific 
TCL cells cross-react in the CD23 induction assay, in partic- 
ular, SEB, SEC1, SEC2, SEC3. In contrast,  C1 + T cells are 
not well represented among non-crossreactive TSST-1 or SEE- 
activated T  cells.  T  cells  expanded by weekly retriggering 
with SEB or SEC  1 and autologous APC  show a marked 
fall off in the percentage of C1 + T  cell (Table 2). We inter- 
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Figure 1.  PBL (upper  right); the CD4 + MAM-reactive  T cell line used 
for immumzation (lower right); or a CD4 + SEE-reactive T cell derived 
from the same  donor (lower  left) were  analyzed  by indirect immunofluores- 
cence staining for reactivity with the C1 mAb. Background staining of 
PBL with PBS and fluoresceinated anti-mouse Ig is shown (upper left). 
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T  cells  expressing  several  TCK  VB  gene  family  products 
among which C1 §  T  cells are a minor component  with a 
relatively  low binding affinity for SEB. In contrast,  C1 + T 
cells are greatly expanded in short-term cultures of MAM- 
activated  T  cells and remain well represented.  In the experi- 
ment  presented in Table 2,  the percentage  of C1 +  T  cells 
decreases somewhat over time in the culture stimulated weekly 
by MAM.  However, in most experiments,  C1 + T  cells rep- 
resent between  50  and  60%  of TCL repetitively  triggered 
with MAM (Fig.  1). Finally, it is of interest that C1 + T cells 
comprise  a  stable  population  of 15-20%  of SEC2 reactive 
TCL cells.  These results  suggest that C1 + T  cells represent 
the major population of human T cells reactive with MAM, 
and a significant  fraction  of the SEC2-responsive  T  cell pool. 
Table  2.  Pe@heral Blood T  Cells Triggered with MAM Are 
Highly Enriched in  CI 
Percentage  of T  cells staining 
positively  with anti-TCR mAbs 
Superantigen 
stimulus  C1  C37  OT145  $511  Ti3a 
Figure 2.  Immunoprecipitation  of TCK by C1 mAb: Radioiodinated 
MAM-reactive TCL cells were lysed and precipitated with the indicated 
mAb. r  is a negative  control  mAb (IgG1);  W6/32 (anti-class  I MHC); 
CD3 was precipitated with mAb 454 (59); OT145 is specific for TCK 
expressing VB6.7a gene products. 
Table  1.  Percentage  of CI + T  Cells in CD4 and CD8 
Subt,opulations 
C1 +/CD4 §  C1 +/CD8 + 
Adult bloods 
Cord bloods 
Mean  _+  SD 
1  14.00  3.77 
2  6.40  2.30 
3  7.98  5.56 
4  5.65  7.87 
5  6.63  11.32 
1  7.69  3.76 
2  4.75  3.98 
3  3.99  3.20 
4  3.45  4.48 
5  5.65  7.87 
6.62  +  2.83  5.41  _+  2.64 
MAM  55.6  0.0  2.5  2.5  5.6 
TSST  0.6  1.3  2.8  0.8  1.9 
SEA  5.1  0.6  2.9  2.9  5.9 
Primary  SEB  26.5  0.4  2.7  9.0  1.5 
culture  SEE  3.0  3.4  1.2  0.2  12.5 
SEC1  17.8  4.8  3.0  7.3  5.2 
SEC2  15.1  1.8  0.0  7.1  1.7 
SEC3  9.2  4.1  1.9  4.5  6.2 
MAM  39.4  1.2  0.2  2.8  2.7 
TSST  0.2  0.0  1.1  0.0  0.0 
SEA  1.2  0.0  0.0  0.0  0.0 
Secondary  SEB  10.1  0.6  2.2  6.4  0.7 
culture  SEE  0.6  1.2  0.5  0.1  15.3 
SEC1  9.4  1.0  1.4  2.0  3.1 
SEC2  15.5  1.6  0.0  5.0  0.4 
SEC3  6.9  0.0  0.0  0.8  0.0 
MAM  32.4  0.2  0.0  1.5  2.7 
TSST  0.0  0.1  0.3  2.6  1.6 
SEA  0.7  0.3  0.4  0.7  0.9 
Tertiary  SEB  7.3  0.5  0.0  3.3  3.3 
culture  SEE  0.1  0.3  2.1  1.3  11.9 
SEC1  8.7  0.6  0.7  2.5  0.9 
SEC2  17.0  0.0  0.0  7.4  0.0 
SEC3  6.2  0.0  0.1  1.8  0.2 
Cord blood lymphocytes and PBL obtained from normal adult donors 
were analyzed  by two-color immunofluorescence  staining for distribu- 
tion of C1 + T cells in the CD4 + and the CD8 + T  cell  subsets. 
PBL were activated weekly with x-irradiated autologous APC and the 
indicated SA. The percentage  of T cells staining with each of the anti- 
TCR MAbs was assessed each week 6 d after triggering. 
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[3H]Tdr incorporation 
induced by: 
Description of  MAM  SEE  TSST-1 
responder population  Media  APCxr  APCx,  APCx,  APC,r 
%  C1 +  cpm 
Exp.  1  E §  3.5  85  6,681  37,978  39,313  69,033 
E + C1-  0.3  53  1,159  24,226  25,667  55,629 
E §  C37-  2.8  2,969  1,837  25,509  23,847  59,855 
Exp.  2  E +  4.6  82  1,170  26,748  122,655  54,603 
E § C1-  0.9  267  1,348  27,721  99,509  46,956 
E § C37-  4.1  239  1,184  29,513  77,742  58,827 
Peripheral blood T lymphocytes were depleted of T cells reacting with anti-TCR  MAbs C1 or C37 using magnetic beads coated with anti--mouse 
Ig. Untreated or MAb-depleted T cells were assayed, in triplicate, for proliferative responses against medium alone, autologous APC,~, or the indi- 
cated SA in the presence of autologous APCxr. The percentage of CI + T cells present in each responder T cell population was detected by immu- 
nofluorescence staining. Experiments 1 and 2 describe the results of separate studies involving two different normal donors. 
C1 +  T  Cells are MAM-reactive.  To formally prove that 
C1 +  T  cells are MAM-reactive,  we took advantage of the 
fact that anti-TCR mAbs are mitogenic, allowing the selec- 
tive activation and expansion of T  cells expressing the rele- 
vant TCR epitope.  Thus,  aliquots of tonsillar T  cells were 
treated with saturating concentrations of mAb C1 or either 
of two non cross-reactive TCR Vfl gene product specific mAb: 
C37 (Vfl 5.2/5.3), and OT145 (V/3 6.7a), TCL were gener- 
ated as described in the methods section. These lines are vir- 
tually pure with respect to reactivity with the relevant anti- 
TCR  mAb  (see legend  to Fig.  3). 
While each line contained a CD4 + T  cell fraction, CD8 + 
T cells predominated, comprising 60-80% of the TCL popu- 
lation.  We therefore assessed  a CD8 + T  cell-dependent func- 
tion, by asking if these TCL cells could lyse MHC dass II 
positive target cells in a SA dependent manner. In the experi- 
ment depicted in Fig. 3, no significant lysis of untreated 8866 
target  cells by any of the TCL is observed.  However,  the 
C1 + TCL selectively lyses MAM-bearing  8866 cells, while 
both  the  OT145 +  and  C37 +  TCL  cells  effectively lyse 
TSST-1 bearing,  but  not MAM-bearing,  targets.  It  should 
be noted that the proliferative response of human T  cells to 
TSST-1 is reportedly dominated by the Vfi2 + fraction (40). 
We interpret the lysis of TSST-1 bearing targets by Vfi6.7a + 
and V~ 5.2/5.3 + TCL cells to represent another example of 
the cross-reactivity of activated human T  cells to S.  aureus- 
derived SA (39). The experiment depicted in Fig. 3 has been 
performed on three separate occasions, using C1 § TCL in- 
dependently derived from different donors. In all studies, the 
results are similar to those shown.  Thus, C1 + T  cells, acti- 
vated and expanded with mAb C1, demonstrate functional 
specificity for MAM. 
MAM-reactive Human  T  Cells Include a C1 Negative Popu- 
lation.  The expansion of C1 + c,.'lls in short-term cultures 
of SE-activated T  cells (Table 2) indicates that C1 + T  cells 
can account for the pattern of SA responsiveness associated 
with MAM-reactive TCL. However, this data does not rule 
out the existence of C1 -  MAM-reactive T  cells. Indeed, the 
observation that repetitive triggering of MAM-reactive T cells 
with MAM results in a TCL that is is maximally 50-60% 
C1 +  provides indirect evidence that  a  C1-  MAM-reactive 
T  cell population exists.  To address  this point,  aliquots of 
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Figure 3.  Tonsillar T cells, expanded in culture by weekly activation 
with an anti-TCR mAb, goat anti-Ig-coated magnetic beads, and IL-2, 
triplicate at the effector to target ratios indicated for cytotoxic activity 
against sICr release assay. Target cells consisted of a lymphoblastoid  B cell 
line 8866 either untreated (8866) or "pulsed" for I h at 37~  with MAM 
(8866~) or TSST-1 (8866TSST-0.  Depicted are the cytotoxic activities 
of mAb C37 activated T cells (A); mAb OT145 activated T cells ([-1); 
and mAb C1 activated  T cells (0). The phenotype of these three cell lines 
at the time of assay are as follows: mAb C37 activated =  99% C37 +, 
22% CD4 +, 77% CDS+;  mAb OT145 activated =  100% OT145+; 
16% CD4+; 85% CDS+; mAb C1 activated = 99% C1 +, 43% CD4 +, 
61% CD8 +  . 
895  Friedman  et al. Figure 4.  Specific  PCIL amplification of V~17 gene products from a C1 + TCL. The c.DNA from three cell lines (OT145  +  , C37 +  , C1 +) was amplified 
with Co~ primers, C~-VB2  primers, C/3-VB5.2/5.3 primers, CB-V/36  primers, or CB-V~17 primers. Specific  bands are indicated with arrows. In each 
case, the band migrates as expected based on the estimated size of the amplified segment. 
fresh peripheral  T  cells were depleted of C1 +  or C37 + T 
cells by treatment with the relevant mAb followed by phys- 
ical removal of the reactive T cells using magnetic beads bearing 
goat anti-mouse IgG. As shown in Table 3, while this pro- 
cedure efficiently reduces or eliminates the C1 + T  cell pool, 
as detected by immunofluorescence  staining,  the prolifera- 
tive response to MAM was not  affected. We should point 
out that  T  cell populations depleted of C1 + cells maintain 
strong proliferative responses over a wide range of MAM con- 
centrations (6 log dilutions). In additional studies, we deter- 
mined  that  both  C1-  MAM-reactive  TCL  and  the  C1 + 
TCL specifically  and efficiently lyse the MAM bearing 8866 
target cells (data not shown). Taken together, these findings 
support the existence ofa MAM-reactive human T cell popu- 
lation  distinct  from that  which expresses the  C1  epitope. 
mAb CI Is Specific for TCR  Vj8 17.  TCL were prepared 
with three mAb:  OT145 (V/~6.7a),  C37 (VB5.2/5.3),  and 
C1, as described above. Each of these polyclonal T  cell lines 
contained >98% cells positive with the relevant mAb. RNA 
was isolated and cDNA synthesized with reverse  transcrip- 
tase.  Aliquots of cDNA were PCR amplified with different 
primer combinations. Fig. 4 shows that each cell line expressed 
a specific V~ As expected, the OT145 + cells expressed V/36, 
and the C37 + cells expressed VB5.2/5.3.  The C1 + cells ex- 
pressed VB17. None of these TCL expressed VB2 and all of 
them expressed Col.  In other experiments  (not shown) the 
C1 + cell line was analyzed with primers  specific for VB1 - 
VB20.  No  primer  combinations  other  than  VB17-CB 
amplified a B chain product.  Thus,  VB17 appears to repre- 
sent the sole VB gene product recognized by C1.  V~17 is 
896 
thought  to represent  a Vfl family with a single gene copy 
based on counting bands  on Southern blots  (41-43). 
Discussion 
While all microbial SA are mitogenic for human PBL, the 
functional response induced by MAM is unique in that MAM 
stimulation of PBL consistently results in T  cell-dependent 
B cell activation  characterized by polyclonal IgM and IgG 
production  (Crow,  M.  K.,  Z.  Chu,  B.  Ravina,  G.  Zagon, 
J. R. Tumang, B. C. Cole, and S. M. Friedman, manuscript 
submitted  for  publication).  This  evidence  of  the  im- 
munostimulatory  effects of MAM on the humoral  arm of 
the human immune system suggested that a more precise char- 
acterization  of MAM-reactive human T  cells is warranted. 
In the mouse, MAM has been shown to behave as a classic 
microbial SA,  selectively inducing  the proliferation  of Vfl 
8 + and Vfl 6 + murine T  cells  (18).  While MAM is mito- 
genic for human  T  cells,  the level  of proliferation  induced 
is quite modest compared to that triggered by the Staphylo- 
coccus aureus-derived SA, and no data exists regarding TCR 
V gene dependence of MAM recognition. The mAb described 
in this report, C1, provides the first direct evidence that MAM- 
reactive human T cells utilize a restricted group of TCR V3 
gene products, mAb C1 recognizes a disulfide linked hetero- 
dimer, consistent with the c~/~ TCR, on approximately 3--6% 
of peripheral T  cells.  As with other mAb specific for TCR 
V gene products, C1 reacts with a small fraction of both the 
CD4 +  and  CD8 +  subsets  of all  donors  tested,  including 
cord blood T  cells.  With respect to SA recognition,  it was 
Generation of A Monoclonal Antibody against V317 determined that MAM-reactive TCL are greatly enriched in 
C1 + cells, while TCL responsive to SA with which MAM- 
reactive TCL  are less crossreactive, SEE  and TSST-1, are 
depleted of C1 + T cells. Studies employing the polymerase 
chain reaction to amplify TCR 3  chain cDNA from C1 + 
TCL cells demonstrate that C1 identifies an epitope expressed 
on the VB  17 gene product. Taken together, these results 
show that MAM recognition by human T cells is restricted 
by TCK V3 gene usage and that a major fraction of MAM- 
reactive human T  cells are VB17  +. 
From a technical standpoint, it is worth noting that mAb 
C1 is a unique example of a TCR V gene specific  mAb gener- 
ated by immunizing with a polyclonal T cell population.  As 
discussed above, MAM is a relatively  weak mitogen for human 
T cells, suggesting a restricted population of MAM-reactive 
T cells. Presumably, the highly restricted usage of V3 genes 
among the MAM-reactive  immunizing TCL cells allowed 
our immunization strategy to be successful. Consistent with 
this, staining data demonstrate that the TCR. epitope recog- 
nized by mAb C1 is expressed not only on >60% of the im- 
munizing TCL, which had been retriggered repetitively with 
MAM, but is also present  on a relatively large fraction of 
peripheral  T  cells activated by MAM for only several days 
in primary short term cultures (Table 2). The successful ap- 
plication of this technique, utilizing TCL responsive to other 
microbial SA as immunogens, could greatly expand the avail- 
able panel of mAbs against human TCR V gene products. 
The mechanism which accounts for the striking capacity 
of MAM to induce polyclonal Ig production by unfractionated 
PBL remains unexplained.  Most simply, perhaps,  the pool 
of MAM-reactive  T  cells may be quite limited in number 
as compared to T cells reactive with other SA. Thus, a limited 
pool of potentially responsive T cells could account for a rel- 
atively weak MAM-induced T cell proliferative response, but 
su~cient lymphokine secretion to promote B cell activation. 
In this regard, Fleischer et al. (39) have reported that while 
40-70% of randomly generated human T cell clones respond 
to  one  or  several Staphylococcus aureus-derived SA,  none 
responded to MAM. These investigators have suggested that 
MAM-reactive human T cells may represent only 5% of all 
T cells (44). Utilizing mAb C1 to address this issue, we found 
that on average, C1 + T cells represent approximately 5% of 
the peripheral T cell pool. While a firm conclusion that all 
C1 § T  cells are MAM reactive must await the functional 
analysis of cloned C1 + T  cells, the marked enrichment of 
C1 § T cells among T cell "blasts"  in even short-term cul- 
tures of MAM activated PBL and marked depletion of C1 + 
T cells from the MAM nonresponsive "small" T cell fraction 
provides strong, albeit indirect, evidence that this will prove 
the case. However,  the existence of MAM-reactive  T  cells 
in addition to the C1 + population is suggested by three lines 
of experimental evidence. First,  resting peripheral blood T 
cells, depleted of C1 + cells, show an undiminished prolifer- 
ative response to MAM over a wide range of SA concentra- 
tions. Second, 40-60% ofT cells which persist in long term 
cultures maintained by repetitive  retriggering with MAM 
plus autologous APC are C1-. Third, MAM reactive TCL 
which have been depleted of C1 § T cells exhibit potent, SA 
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specific lysis of MAM bearing target cells. Studies are in prog- 
ress utilizing C1- MAM-reactive TCL cells to identify other 
V3 genes used by MAM-reactive T cells and to generate mAbs 
against their products.  Using such a panel of mAbs against 
MAM-reactive TCK V gene families, one could hope to de- 
termine if MAM's interesting functional effects on human 
PBL relate to: (a) the limited pool of MAM-responsive  T 
cells; (b) unique functional properties  of MAM-responsive 
T cells; or (c) structural differences  among the SA themselves. 
In this regard, a recent report has demonstrated the capacity 
of TSST-1, but not SEB, to activate human B cells by binding 
to their MHC class II surface antigens  (45). 
There is considerable evidence of selective TCR V3 gene 
usage among rodent T cells which mediate a number of ex- 
perimental autoimmune diseases. For example, in experimental 
allergic encephalomyelitis (EAE), V38.2 + T cells play a cen- 
tral role. In five different strains of rat, encephalitogenic T 
cell clones and hybridomas, reactive  against myelin  basic protein 
(MBP) peptide fragments, are uniformly V38.2 + (46). Simi- 
larly, V38.2 is expressed on over 85%  of T  cells reacting 
to the encephalitogenic MBP peptide in strains of mice sus- 
ceptible to EAE (47, 48). Moreover, the in vivo administra- 
tion ofmAb specific for V38.2 has been shown to both pro- 
tect  mice from  the  development  of EAE  induced by  a 
subsequent challenge with MBP, and to ameliorate the clin- 
ical course of EAE in mice already affected (47). In another 
disease model, collagen-induced  arthritis,  T  cells reactive 
against type II collagen which are capable of transferring ar- 
thritis to naive syngeneic mice are virtually all V/~8.2  + (49). 
These observations suggest that expression of the VBS.2 gene 
product may be associated with an autoimmune T cell pool 
in rodents.  For instance,  T  cells derived from the CD4- 
CD8- V38.2 expressing thymocyte subpopulations (50-52). 
In this context, the observation that human MAM-reactive 
T  cells identified  by mAb C1  are V317 + is  of interest. 
Amino acid sequence analysis has demonstrated a close rela- 
tionship between the products of murine V38 genes, which 
are expressed by MAM-reactive murine T cells (53), and sev- 
eral human TCR V3 gene families, including V317  (54). 
Moreover, there are reports implicating V317 usage by au- 
toimmune human T cells. For example, Wucherpfennig et 
al. (55) reported expanded populations  of MBP-reactive T 
cells in the peripheral blood of multiple sclerosis (MS) pa- 
tients, and preferential usage of V317 + among those T cells 
reactive against an encephalotogenic MBP peptide presented 
in association with DR2 and DR3, two MHC class II genes 
overrepresented in the MS patient population. In addition 
V317 + T cells have been reported to be enriched among ac- 
tivated T cells isolated from the synovial tissue of patients 
with rheumatoid arthritis  (RA) (56). It should be empha- 
sized, that these reports require confirmation as additional 
studies have suggested the predominant usage of other human 
TCR V3 genes in both diseases (57, 58). We would suggest, 
however, that mAb C1  may be of considerable utility in 
defining a potential role for V3 17 + T cell participation  in 
the pathogenesis of human autoimmune disorders, including 
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